| Literature DB >> 35109837 |
Ryosuke Hishimura1, Tomohiro Onodera2, Yasumitsu Ohkoshi3, Kazufumi Okada4, Masatake Matsuoka1, Shinji Matsubara1, Koji Iwasaki5, Eiji Kondo6, Norimasa Iwasaki1.
Abstract
BACKGROUND: Tranexamic acid (TXA) is used as a synthetic anti-fibrinolytic agent for total knee arthroplasty (TKA) to reduce postoperative bleeding. Though the effects on bleeding reduction of several methods of administering TXA have been demonstrated, the optimal method remains controversial. Recently, the hemostatic effect of periarticular local injection of TXA during TKA was reported. Although this method can be expected to suppress postoperative bleeding without placing a drain, its hemostatic effect has not yet been assessed in comparison with local injection and other methods of administering TXA. The aim of this randomized, prospective study was to assess the efficacy of local injection of TXA during TKA.Entities:
Keywords: Drain clamping; Periarticular local injection; Total knee arthroplasty (TKA); Tranexamic acid (TXA)
Mesh:
Substances:
Year: 2022 PMID: 35109837 PMCID: PMC8808990 DOI: 10.1186/s12891-022-05058-6
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Inclusion and Exclusion Criteria
| Inclusion Criteria | Exclusion Criteria |
|---|---|
| Adult over 20 years of age | Sever renal disfunction |
| Willing and able to give consent | Past history of thrombosis |
| Extensive synovectomy during surgery | |
| Use of the allogenic blood transfusion | |
| Use of another prothesis due to procedural change | |
| Patients whose drain was clogged | |
| Patients who can not prepare the autologous blood |
Fig. 1Flow diagram presents the number of patients included through various stages of the study. Eleven patients met the exclusion criteria and 109 patients were included in the analysis
Patient Demographics
| Variables | Group L | Group D |
|---|---|---|
| TKAs | ||
| Ages (y) | 73.0 ± 6.06 | 72.6 ± 6.07 |
| BMI (kg/m2) | 27.6 ± 3.85 | 28.1 ± 3.51 |
| Sex (Female/Male) | 49/8 | 48/4 |
| Diagnosis (OA/others) | 54/3 | 50/2 |
Values are given as the mean and the standard deviation
OA indicates osteoarthritis, BMI Body mass index
Postoperative clinical outcomes
| Outcomes | Group L | Group D | |
|---|---|---|---|
| CTBL (ml) | 883 ± 248 | 841 ± 257 | 0.564 |
| DBL (ml) | 395 ± 130 | 276 ± 78.8 | < 0.0001 |
| HBL (ml) | 488 ± 269 | 565 ± 261 | 0.1315 |
| D-dimer (μg/ml) | 6.50 ± 2.80 | 5.93 ± 2.71 | 0.285 |
| NRS at POD 5 | 1.96 ± 2.45 | 2.65 ± 2.70 | 0.195 |
| NRS at POD 10 | 1.81 ± 2.32 | 2.54 ± 2.56 | 0.131 |
| ROM at POD 14 | |||
| Extension (°) | −0.93 ± 2.32 | −1.59 ± 2.92 | 0.284 |
| Flexion (°) | 106 ± 15.1 | 106 ± 14.3 | 0.886 |
| Circumference of the leg | |||
| Thigh girth at POD 5 (%) | 107 ± 4.80 | 107 ± 5.25 | 0.84 |
| Suprapatellar girth at POD 5 (%) | 109 ± 4.74 | 109 ± 4.39 | 0.556 |
| Calf girth at POD 5 (%) | 102 ± 3.96 | 103 ± 5.11 | 0.575 |
| Thigh girth at POD 10 (%) | 104 ± 4.11 | 103 ± 4.32 | 0.77 |
| Suprapatellar girth at POD 10 (%) | 107 ± 5.44 | 106 ± 4.34 | 0.67 |
| Calf girth at POD 10 (%) | 101 ± 4.75 | 101 ± 7.15 | 0.79 |
Values are given as the mean and the standard deviation
CTBL indicates calculated total blood loss. DBL Drained blood loss, HBL Hidden blood loss, NRS Numerical rating scale, POD Postoperative day, ROM Range of motion
Significance was accepted with a one-sided p-value < 0.025 for the CTBL and with a two-sided p-value < 0.05 for the secondary outcome measures